Call Us + 33 1 84 88 31 00

Article R5121-196 of the French Public Health Code

When a person authorised to prescribe, dispense or administer medicinal products becomes aware of an adverse reaction which may be due to a blood-derived medicinal product, he/she shall report it immediately, even if he/she has not personally prescribed, dispensed or administered the medicinal product in question. The report must be sent : 1° When the medicinal product has been dispensed in a health establishment or a health cooperation grouping, to…

Read More »

Article R5121-197 of the French Public Health Code

The correspondent mentioned in article R. 5121-181 who receives the report provided for in article R. 5121-196 immediately forwards it to the regional pharmacovigilance centre. If he is otherwise aware of an adverse reaction likely to be due to a blood-derived medicinal product, he shall report it immediately to the regional centre. When adverse reactions are likely to be due to the administration of blood-derived medicinal products to a patient…

Read More »

Article R5121-198 of the French Public Health Code

The regional pharmacovigilance centres inform the Agence nationale de sécurité du médicament et des produits de santé on the same day of the reports of adverse reactions likely to be due to a blood-derived medicinal product that they have received.

Read More »

Article R5121-199 of the French Public Health Code

Organisations or companies exploiting blood-derived medicinal products which have knowledge of adverse reactions likely to be due to these medicinal products inform the Director General of the Agence nationale de sécurité du médicament et des produits de santé under the conditions set out in articles R. 5121-171 to R. 5121-173.

Read More »

Article R5121-200 of the French Public Health Code

Blood establishments and organisations or companies manufacturing or exploiting blood-derived medicinal products which are aware of information likely to cast doubt on the quality of blood or plasma intended for fractionation inform each other. Blood transfusion establishments shall inform the President of the Etablissement Français du Sang. Organisations or companies manufacturing or exploiting medicinal products inform the Agence nationale de sécurité du médicament et des produits de santé. The Agence…

Read More »

Article R5121-201-4 of the French Public Health Code

The pharmacovigilance carried out on individually prepared advanced therapy medicinal products includes monitoring to ensure traceability between the various stages, from the removal of tissues, cells or blood, where applicable, to the administration of the individually prepared advanced therapy medicinal product to a patient. This traceability also applies to the research referred to in Article L. 1121-1. This traceability supplements the requirements relating to the traceability of tissues and cells…

Read More »

Article R5121-201-5 of the French Public Health Code

I.-Any establishment or body referred to in Article L. 4211-9-1 or any pharmaceutical establishment referred to in Articles L. 5124-1 or L. 5124-9-1 shall set up and keep up to date a system ensuring the traceability of advanced therapy medicinal products prepared on an ad hoc basis. II – Establishments which prepare punctually prepared advanced therapy medicinal products shall keep data enabling the identification of samples of tissues, cells, blood…

Read More »

Article R5121-201-6 of the French Public Health Code

Before administering the punctually prepared advanced therapy medicinal product, the health professional in the health establishment must ensure that the information required for the traceability of the medicinal product appears on the labelling of its immediate packaging. After administering it, the health professional draws up an administration record which includes the following information: 1° The name of the advanced therapy medicinal product prepared on an ad hoc basis; 2° The…

Read More »

Article R5121-201-7 of the French Public Health Code

The data referred to in II and III of Article R. 5121-201-5 and a copy of the administration record referred to in Article R. 5121-201-6 shall be kept by the establishments referred to in Article R. 5121-201-5 for at least thirty years after the expiry date of the advanced therapy medicinal product prepared on an ad hoc basis.

Read More »

Contact a French lawyer now

Contact a French Business Lawyer

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call us at +33 (0) 1 84 88 31 00 or send us an email.

Useful links

You have a question in French Business Law?

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call +33 (0) 1 84 88 31 00 or send us an email.

All information exchanged through this website will be communicated to lawyers registered with a French Bar and will remain confidential.